Sphinganine (d18:0) (Synonyms: Dihydrosphingosine, D-erythro-Dihydrosphingosine, Dihydro-D-erythro Sphingosine, Sphinganine, DerythroSphinganine) |
| Katalog-Nr.GC40794 |
D-Erythro-Dihydrosphingosin hemmt direkt die zytosolische Phospholipase A2α (cPLA2α) AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 764-22-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sphinganine (d18:0) is an intermediate in the sphingolipid metabolic pathway[1]. Sphinganine (d18:0) is a precursor of ceramide and sphingosine and a substrate for sphingosine kinase, which produces sphingosine-1-phosphate[2]. Sphinganine (d18:0) can be used as a standard for the quantification of epidermal ceramide by liquid chromatography-tandem mass spectrometry[3]. Sphinganine (d18:0) can be used to prepare bovine serum albumin lipid complexes to study their effects on the inhibition of non-lysosomal glucosylceramidase β2 (GBA2)[4]. Sphinganine levels are significantly increased in response to certain mycotoxins, including fumonisins, and in certain cancers[5]. Sphinganine can block the activation of protein kinase C[6].
References:
[1]Wigger D, Gulbins E, Kleuser B, et al. Monitoring the sphingolipid de novo synthesis by stable-isotope labeling and liquid chromatography-mass spectrometry[J]. Frontiers in Cell and Developmental Biology, 2019, 7: 210.
[2]Zheng W, Kollmeyer J, Symolon H, et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2006, 1758(12): 1864-1884.
[3]Wang Z, Kirkwood J S, Taylor A W, et al. Transcription factor Ctip2 controls epidermal lipid metabolism and regulates expression of genes involved in sphingolipid biosynthesis during skin development[J]. Journal of Investigative Dermatology, 2013, 133(3): 668-676.
[4]Schonauer S, Körschen H G, Penno A, et al. Identification of a feedback loop involving β-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease[J]. Journal of Biological Chemistry, 2017, 292(15): 6177-6189.
[5]Shephard G S, Van Der Westhuizen L, Sewram V. Biomarkers of exposure to fumonisin mycotoxins: a review[J]. Food additives and contaminants, 2007, 24(10): 1196-1201.
[6]Smith E R, Merrill Jr A H, Obeid L M, et al. Effects of sphingosine and other sphingolipids on protein kinase C[M]//Methods in enzymology. Academic Press, 2000, 312: 361-373.
| Cas No. | 764-22-7 | SDF | |
| Überlieferungen | Dihydrosphingosine, D-erythro-Dihydrosphingosine, Dihydro-D-erythro Sphingosine, Sphinganine, DerythroSphinganine | ||
| Canonical SMILES | OC[C@H](N)[C@H](O)CCCCCCCCCCCCCCC | ||
| Formula | C18H39NO2 | M.Wt | 301.5 |
| Löslichkeit | DMSO:3mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3167 mL | 16.5837 mL | 33.1675 mL |
| 5 mM | 0.6633 mL | 3.3167 mL | 6.6335 mL |
| 10 mM | 0.3317 mL | 1.6584 mL | 3.3167 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *